Corcept Therapeutics Incorporated
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Corcept Therapeutics Incorporated
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.
Crunch time is coming for a handful of companies expecting hugely consequential clinical readouts by the end of Q1 2024.
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
- Other Names / Subsidiaries
- Corcept Therapeutics Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.